RU2003108745A - METHOD FOR OBTAINING OLANZAPINE HYDRATES AND TRANSFORMING THEM IN CRYSTAL FORMS OF OLANZAPINE - Google Patents

METHOD FOR OBTAINING OLANZAPINE HYDRATES AND TRANSFORMING THEM IN CRYSTAL FORMS OF OLANZAPINE Download PDF

Info

Publication number
RU2003108745A
RU2003108745A RU2003108745/04A RU2003108745A RU2003108745A RU 2003108745 A RU2003108745 A RU 2003108745A RU 2003108745/04 A RU2003108745/04 A RU 2003108745/04A RU 2003108745 A RU2003108745 A RU 2003108745A RU 2003108745 A RU2003108745 A RU 2003108745A
Authority
RU
Russia
Prior art keywords
methyl
olanzapine
thieno
hydrochloride
benzodiazepine
Prior art date
Application number
RU2003108745/04A
Other languages
Russian (ru)
Inventor
Бучи Редди РЕГУРИ (IN)
Бучи Редди РЕГУРИ
Рамеш ЧАККА (IN)
Рамеш ЧАККА
Роберт КОПРОВСКИ (US)
Роберт КОПРОВСКИ
Original Assignee
Др. Редди`З Лабораториз Лтд. (In)
Др. Редди`З Лабораториз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Др. Редди`З Лабораториз Лтд. (In), Др. Редди`З Лабораториз Лтд. filed Critical Др. Редди`З Лабораториз Лтд. (In)
Publication of RU2003108745A publication Critical patent/RU2003108745A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Claims (21)

1. Соединение, которое представляет собой моногидрат-1 оланзапина.1. The compound, which is olanzapine monohydrate-1. 2. Соединение, которое представляет собой дигидрат-1 оланзапина.2. A compound that is olanzapine dihydrate-1. 3. Соединение, которое представляет собой моногидрат-1 оланзапина, имеющее следующую рентгеновскую дифракцию на порошке:3. The compound, which is olanzapine monohydrate-1, having the following x-ray powder diffraction: значение dd value I/I0 I / I 0 10.17610.176 100100 6.89956.8995 77 6.35676.3567 1212 6.17146.1714 11eleven 4.87564.8756 5151 4.72624.7262 2222 4.59054.5905 3434 4.49374.4937 77 4.43154.4315 13thirteen 4.34144.3414 1010 4.14114.1411 66 3.91743.9174 9nine 3.86693.8669 2323 3.78573.7857 2626 3.64803.6480 9nine 3.57013.5701 15fifteen 3.44513.4451 33 3.25003.2500 44 3.20653.2065 44 2.96462.9646 55 2.87152.8715 33 2.85722.8572 33 2.68682.6868 33 2.67432.6743 33
4. Соединение, которое представляет собой дигидрат-1 оланзапина, имеющее следующую рентгеновскую дифракцию на порошке:4. A compound that is olanzapine dihydrate-1 having the following x-ray powder diffraction: значение dd value I/I0 I / I 0 9.99499.9949 100 100 9.68879.6887 77 7.04187.0418 22 6.41176.4117 22 6.24956.2495 77 6.12056.1205 66 5.45345.4534 66 5.23585.2358 22 4.82304.8230 3333 4.71624.7162 9nine 4.57174.5717 15fifteen 4.48474.4847 66 4,39244.3924 88 4.30804.3080 44 4.20704.2070 33 4.07354.0735 33 3.99743.9974 33 3.92423.9242 9nine 3.84383.8438 1212 3.76993.7699 9nine 3.73863.7386 13thirteen 3.68373.6837 33 3.65093.6509 44 3.60723.6072 55 3.52563.5256 11eleven 3.42423.4242 22 3.17733.1773 22 3.12073.1207 22 2.99172.9917 22 2.95692.9569 33 2.87332.8733 22 2.84832.8483 22 2.78952.7895 22
5. Способ получения моногидрата-1 оланзапина, включающий следующие стадии:5. A method of producing olanzapine monohydrate-1, comprising the following steps: a) кипячение с обратным холодильником смеси хлоргидрата 4-амино-2-метил-10Н-тиено-[2,3-b][1,5]бензодиазепина, N-метилпиперазина, диметилсульфоксида и толуола в течение 5-20 ч;a) refluxing a mixture of 4-amino-2-methyl-10H-thieno [2,3-b] [1,5] benzodiazepine hydrochloride, N-methylpiperazine, dimethyl sulfoxide and toluene hydrochloride for 5-20 hours; b) охлаждение смеси до температуры от 20 до 90°С;b) cooling the mixture to a temperature of from 20 to 90 ° C; c) добавление воды;c) adding water; d) охлаждение смеси до температуры от -5 до 25°С и перемешивание в течение 2-10 ч;d) cooling the mixture to a temperature of from -5 to 25 ° C and stirring for 2-10 hours; e) фильтрование смеси и промывание водой; иe) filtering the mixture and washing with water; and f) сушка при температуре от 30 до 50°С до постоянного веса.f) drying at a temperature of from 30 to 50 ° C to constant weight. 6. Способ по пункту 5, в котором соотношение количества хлоргидрата 4-амино-2-метил-10Н-тиено-[2,3-b][1,5]бензодиазепина и N-метилпиперазина составляет 1:2,0-8,4.6. The method according to paragraph 5, in which the ratio of the amount of 4-amino-2-methyl-10H-thieno [2,3-b] [1,5] benzodiazepine hydrochloride and N-methylpiperazine hydrochloride is 1: 2.0-8, 4. 7. Способ по пункту 5, в котором объем диметилсульфоксида представляет собой 2-8 кратные значения молей хлоргидрата 4-амино-2-метил-10Н-тиено-[2,3-b][1,5] бензодиазепина.7. The method according to paragraph 5, wherein the volume of dimethyl sulfoxide is 2-8 times the moles of 4-amino-2-methyl-10H-thieno [2,3-b] [1,5] benzodiazepine hydrochloride. 8. Способ по пункту 5, в котором объем толуола представляет собой 3-8 кратные значения молей хлоргидрата 4-амино-2-метил-10Н-тиено-[2,3-b][1,5]бензодиазепина и диметилсульфоксида.8. The method according to claim 5, wherein the toluene volume is 3-8 times the moles of 4-amino-2-methyl-10H-thieno [2,3-b] [1,5] benzodiazepine and dimethyl sulfoxide hydrochloride. 9. Способ получения дигидрата-1 оланзапина, включающий следующие стадии:9. A method of producing olanzapine dihydrate-1, comprising the following steps: a) кипячение с обратным холодильником смеси хлоргидрата 4-амино-2-метил-10Н-тиено-[2,3-b][1,5]бензодиазепина, N-метилпиперазина, диметилсульфоксида и толуола в течение 5 - 20 ч;a) refluxing a mixture of 4-amino-2-methyl-10H-thieno [2,3-b] [1,5] benzodiazepine hydrochloride, N-methylpiperazine, dimethyl sulfoxide and toluene hydrochloride for 5 to 20 hours; b) охлаждение смеси до температуры от 20 до 90°С;b) cooling the mixture to a temperature of from 20 to 90 ° C; c) добавление воды;c) adding water; d) охлаждение смеси до температуры от -5 до 25°С и перемешивание в течение 2-10 ч;d) cooling the mixture to a temperature of from -5 to 25 ° C and stirring for 2-10 hours; e) фильтрование смеси и промывание водой; иe) filtering the mixture and washing with water; and f) сушка при температуре окружающей среды до постоянного веса.f) drying at ambient temperature to constant weight. 10. Способ по пункту 9, в котором соотношение количества хлоргидрата 4-амино-2-метил-10Н-тиено-[2,3-b][1,5]бензодиазепина и N-метилпиперазина составляет 1:2,0-8,4.10. The method according to paragraph 9, in which the ratio of the amount of 4-amino-2-methyl-10H-thieno [2,3-b] [1,5] benzodiazepine hydrochloride and N-methylpiperazine hydrochloride is 1: 2.0-8, 4. 11. Способ по пункту 9, в котором объем диметилсульфоксида представляет собой 2-8 кратные значения молей хлоргидрата 4-амино-2-метил-10Н-тиено-[2,3-b][1,5]бензодиазепина.11. The method according to claim 9, wherein the volume of dimethyl sulfoxide is 2-8 times the moles of 4-amino-2-methyl-10H-thieno [2,3-b] [1,5] benzodiazepine hydrochloride. 12. Способ по пункту 9, в котором объем толуола представляет собой 3-8 кратные значения молей хлоргидрата 4-амино-2-метил-10Н-тиено-[2,3-b][1,5]бензодиазепина.12. The method of claim 9, wherein the toluene volume is 3-8 times the moles of 4-amino-2-methyl-10H-thieno [2,3-b] [1,5] benzodiazepine hydrochloride. 13. Способ получения формы-1 оланзапина из дигидрата-1 оланзапина, который включающий следующие стадии:13. A method of obtaining olanzapine form-1 from olanzapine dihydrate-1, which comprising the following steps: a) перемешивание 2-метил-4-(4-метил-1-пеперазинил)-10Н-тиено-[2,3-b][1,5]бензодиазепина (моногидрат-1 оланзапина) в дихлорметане при кипячении с обратным холодильником до получения прозрачного раствора;a) stirring 2-methyl-4- (4-methyl-1-peperazinyl) -10H-thieno [2,3-b] [1,5] benzodiazepine (olanzapine monohydrate-1) in dichloromethane under reflux to obtaining a clear solution; b) обработка раствора углем;b) treating the solution with coal; c) фильтрование смеси для получения фильтрата;c) filtering the mixture to obtain a filtrate; d) охлаждение фильтрата до температуры от 0 до 5°С;d) cooling the filtrate to a temperature of from 0 to 5 ° C; e) перемешивание в течение 60-90 мин;e) stirring for 60-90 minutes; f) фильтрование для получения твердого вещества, промывание и сушка при температуре от 60 до 70°С до получения постоянного веса.f) filtering to obtain a solid, washing and drying at a temperature of from 60 to 70 ° C until a constant weight is obtained. 14. Способ по пункту 13, где на этапе f) твердое вещество промывают дихлорметаном.14. The method of claim 13, wherein in step f), the solid is washed with dichloromethane. 15. Способ по пункту 13, в котором количество дихлорметана, использующегося на стадии а) имеет значение от 4,5 до 13 по объему/весу хлоргидрата 2-метил-4-(4-метил-1-15. The method according to claim 13, wherein the amount of dichloromethane used in step a) is from 4.5 to 13 by volume / weight of 2-methyl-4- (4-methyl-1- hydrochloride пеперазинил)-10Н-тиено-[2,3-b][1,5]бензодиазепина.peperazinyl) -10H-thieno [2,3-b] [1,5] benzodiazepine. 16. Способ получения формы-1 оланзапина из моногидрата-1 оланзапина, включающий следующие стадии:16. A method of obtaining olanzapine form-1 from olanzapine monohydrate-1, comprising the following steps: a) перемешивание 2-метил-4-(4-метил-1-пеперазинил)-10Н-тиено-[2,3-b][1,5]бензодиазепина в дихлорметане при кипячении с обратным холодильником до получения прозрачного раствора;a) stirring 2-methyl-4- (4-methyl-1-peperazinyl) -10H-thieno [2,3-b] [1,5] benzodiazepine in dichloromethane under reflux until a clear solution is obtained; b) обработка раствора углем;b) treating the solution with coal; c) фильтрование раствора для получения фильтрата;c) filtering the solution to obtain a filtrate; d) охлаждение фильтрата до температуры ниже от 0 до 5°С; иd) cooling the filtrate to a temperature below 0 to 5 ° C; and e) перемешивание в течение 60-90 мин,e) stirring for 60-90 minutes, f) отделение твердого вещества, промывание и сушка при температуре от 60 до 70°С до получения постоянного веса.f) separating the solid, washing and drying at a temperature of from 60 to 70 ° C until a constant weight is obtained. 17. Способ по пункту 16, в котором количество использующегося дихлорметана имеет значение от 4.5 до 13 по объему/весу хлоргидрата 2-метил-4-(4-метил-1-пиперазинил)-10Н-тиено-[2,3-b][1,5]бензодиазепина.17. The method according to paragraph 16, in which the amount of dichloromethane used is from 4.5 to 13 by volume / weight of 2-methyl-4- (4-methyl-1-piperazinyl) -10H-thieno [2,3-b] hydrochloride [1,5] benzodiazepine. 18. Способ по пункту 16, в котором на стадии f) твердое вещество промывают дихлорметаном.18. The method of claim 16, wherein in step f), the solid is washed with dichloromethane. 19. Способ получения формы-1 оланзапина из формы-2 оланзапина, включающий следующие этапы:19. A method of obtaining olanzapine form-1 from olanzapine form-2, comprising the following steps: a) перемешивание хлоргидрата 2-метил-10Н-тиено-[2,3-b][1,5]бензодиазепина (форма-2 оланзапина) в дихлорметане при кипячении с обратным холодильником до получения прозрачного раствора;a) stirring 2-methyl-10H-thieno [2,3-b] [1,5] benzodiazepine hydrochloride (form-2 olanzapine) in dichloromethane under reflux until a clear solution is obtained; b) фильтрование и охлаждение фильтрата до температуры от 0 до 5°С;b) filtering and cooling the filtrate to a temperature of from 0 to 5 ° C; c) перемешивание в течение 60-90 мин; иc) stirring for 60-90 minutes; and d) фильтрование для получения твердого вещества, промывание и сушка при температуре 60-70°С до получения постоянного веса.d) filtering to obtain a solid, washing and drying at a temperature of 60-70 ° C until a constant weight is obtained. 20. Способ по пункту 19, в котором количество использующегося дихлорметана имеет значение от 4,5 до 13 по объему/весу хлоргидрата 2-метил-10Н-тиено-[2,3-b][1,5]бензодиазепина.20. The method according to paragraph 19, in which the amount of dichloromethane used is from 4.5 to 13 by volume / weight of 2-methyl-10H-thieno [2,3-b] [1,5] benzodiazepine hydrochloride. 21. Способ по пункту 19, в котором на стадии d) твердое вещество промывают дихлорметаном.21. The method of claim 19, wherein in step d), the solid is washed with dichloromethane.
RU2003108745/04A 2000-08-31 2001-03-07 METHOD FOR OBTAINING OLANZAPINE HYDRATES AND TRANSFORMING THEM IN CRYSTAL FORMS OF OLANZAPINE RU2003108745A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN711/MAS/2000 2000-08-31
IN709CH2000 2000-08-31
IN709/MAS/2000 2000-08-31
IN711CH2000 2000-08-31

Publications (1)

Publication Number Publication Date
RU2003108745A true RU2003108745A (en) 2005-01-10

Family

ID=26324874

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003108745/04A RU2003108745A (en) 2000-08-31 2001-03-07 METHOD FOR OBTAINING OLANZAPINE HYDRATES AND TRANSFORMING THEM IN CRYSTAL FORMS OF OLANZAPINE

Country Status (12)

Country Link
EP (1) EP1313742A1 (en)
JP (1) JP2004507548A (en)
AU (1) AU2001243475A1 (en)
BR (1) BR0114031A (en)
CA (1) CA2420987A1 (en)
CZ (1) CZ2003566A3 (en)
HU (1) HUP0300875A3 (en)
IL (1) IL154688A0 (en)
NO (1) NO20030926L (en)
RU (1) RU2003108745A (en)
SK (1) SK2502003A3 (en)
WO (1) WO2002018390A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037903A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
WO2003091260A1 (en) * 2002-04-23 2003-11-06 Dr. Reddy's Laboratories Limited Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
WO2003090730A1 (en) * 2002-04-25 2003-11-06 Generics [Uk] Limited Novel crystalline forms of celecoxib and other compounds
PL196814B1 (en) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Method of obtaining polymorphous form of i olansapine
US7297789B2 (en) 2002-05-31 2007-11-20 Sandoz, Inc. Process of preparation of olanzapine form I
SI21270A (en) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Crystal forms of olanzapine and procedures for their preparation
PL202856B1 (en) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Method of obtaining pharmaceutically pure polymorphic form of I olanzapine
EP1575962A1 (en) 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
ATE397611T1 (en) 2003-12-22 2008-06-15 Teva Pharma METHOD FOR PRODUCING OLNZAPINE
AR047459A1 (en) 2004-01-27 2006-01-18 Synthon Bv STABLE SALTS OF 2-METHYL-4- (4-METHYL-1-PIPERAZINIL) -10H-TIENO [2,3-B] [1,5] BENZODIAZEPINA (OLANZAPINA)
WO2005070939A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. Synthesis of olanzapine and intermediates thereof
US20070072845A1 (en) * 2004-02-19 2007-03-29 Davuluri Rammohan Rao Process for the preparation of olanzapine form 1 useful as antipsychotic drug
WO2005107375A2 (en) * 2004-05-06 2005-11-17 Matrix Laboratories Ltd Process for the preparation of olanzapine form-i
US20080009481A1 (en) * 2004-07-14 2008-01-10 Shasun Chemicals And Drugs Limited Process For Making Form I Of Olanzapine
ES2427048T3 (en) 2004-07-14 2013-10-28 Jubilant Life Sciences Limited A process for producing a pure form of 2-methyl-4- (4-methyl-1-piperazinyl) -10H-thieno [2,3-B] [1,5] benzodiazepine
ES2253091B1 (en) 2004-07-27 2007-02-01 Inke, S.A. MIXED SOLVATO OF OLANZAPINE, PROCEDURE FOR OBTAINING AND PROCEDURE OF OBTAINING THE FORM I OF OLANZAPINE FROM THE SAME.
WO2006025065A1 (en) * 2004-08-31 2006-03-09 Lee Pharma Private Limited A process for the preparation of anhydrous olanzopine hydrochloride of form-1
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
PL1838716T3 (en) * 2005-01-05 2011-09-30 Lilly Co Eli Olanzapine pamoate dihydrate
AR053562A1 (en) * 2005-03-21 2007-05-09 Reddys Lab Ltd Dr PROCESS FOR THE PREPARATION OF THE FORM I CRISTALINA DE OLANZAPINA
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
PL381564A1 (en) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent The manner of production of basically clean variety of polymorphic olanzapine
WO2008139228A2 (en) * 2007-05-15 2008-11-20 Generics [Uk] Limited Process for the purification of olanzapine
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
CN102093386B (en) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 A kind of method preparing Zyprexa crystal form II
JP6008734B2 (en) * 2012-12-20 2016-10-19 株式会社トクヤマ Olanzapine type II crystal production method
CN109563057B (en) 2016-05-31 2022-06-24 大鹏药品工业株式会社 Sulfonamide compound or salt thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
KR100516088B1 (en) * 1996-09-23 2005-09-22 일라이 릴리 앤드 캄파니 Olanzapine Dihydrate D

Also Published As

Publication number Publication date
SK2502003A3 (en) 2004-03-02
CZ2003566A3 (en) 2004-01-14
NO20030926D0 (en) 2003-02-27
HUP0300875A2 (en) 2003-12-29
AU2001243475A1 (en) 2002-03-13
CA2420987A1 (en) 2002-03-07
IL154688A0 (en) 2003-09-17
JP2004507548A (en) 2004-03-11
HUP0300875A3 (en) 2005-09-28
NO20030926L (en) 2003-04-24
EP1313742A1 (en) 2003-05-28
BR0114031A (en) 2003-09-09
WO2002018390A1 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
RU2003108745A (en) METHOD FOR OBTAINING OLANZAPINE HYDRATES AND TRANSFORMING THEM IN CRYSTAL FORMS OF OLANZAPINE
RU2266287C2 (en) 2-arylimino-2,3-dihydrothiazoles, methods for their preparing and pharmaceutical composition comprising thereof
CA2432148A1 (en) Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient
JP2007538092A5 (en)
SU1189347A3 (en) Method of producing ergoline derivatives
EP0733634B1 (en) Process for preparing a thieno(2,3-B)(1,5) benzodiazepine derivative
KR20030068164A (en) 1,4-DISUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS URO-SELECTIVE α1-ADRENOCEPTOR BLOCKERS
EG19644A (en) Process for preparing of tricyclic amines as novel cholinesterase inhibitros
KR19980064286A (en) New Form (Type 1) of Doxazosin Mesylate with Polymorphs
CN101809021B (en) Octahydro-pyrrolo[3,4-b]pyrrole N-oxides
KR100659927B1 (en) A new form of the polymorphic serozosin mesylate (Type III)
BR0213172A (en) 8-Amino [1,2,4] triazolo [1,5-a] pyridine-6-carboxylic acid amide
PL1789412T3 (en) Crystalline alfuzosin base
FI67706B (en) FORM OF THERAPEUTIC PREPARATION OF THERAPEUTIC N-5-TETRAZOLYL) -1-OXO-1H-THIAZOLO (3,2-A) PYRIMIDINE-2-CARBOXYL ATR
WO2005107375A3 (en) Process for the preparation of olanzapine form-i
KR102220480B1 (en) Methods for preparing clopidogrel bisulphate and pharmaceutical composition comprising the same
RU2331607C2 (en) Porcelain mixture
WO2020127735A1 (en) New methods of producing (2-amino-4-[6-(4-fluorophenyl)-2-[(4-methyl-1-piperazinyl)methyl]imidazo[2,1-b]thiazol-5-yl]-pyrimidine
CA1128935A (en) Pyrimido(1,6-a)indole derivatives
KR100436504B1 (en) Method for producing bean curd having multiple colors
CZ290318B6 (en) Thiazoloquinoline dioxide, pharmaceutical preparation containing thereof and process of its preparation
WO2006025065A1 (en) A process for the preparation of anhydrous olanzopine hydrochloride of form-1
FI80679B (en) Trans-(±)-1-(alkyl or allyl)-6-oxo-7-alkoxycarbonyl decahydroquinolines which are useful intermediates in the preparation of pyrimido/4,5-g/quinolines which are useful dopamine agonists.
CA2373506A1 (en) Process for manufacturing diazepine derivatives
CN115784707A (en) Preparation process of cryptopoda californica and cryptopoda californica prepared by preparation process

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20050111